Abstract
Rapid and accurate histopathological diagnosis during surgery is critical for clinical decision-making. The prevalent method of intraoperative consultation pathology is time, labour and cost intensive and requires the expertise of trained pathologists. Here, we present an alternative technique for the rapid, label-free analysis of biopsy samples by sequentially assessing the physical phenotype of singularized, suspended cells in high-throughput. This new diagnostic pipeline combines enzyme-free, mechanical dissociation of tissues with real-time deformability cytometry at measurement rates of 100 – 1,000 cells/sec, and machine learning-based analysis. We show that physical phenotype parameters extracted from brightfield images of single cells can be used to distinguish subpopulations of cells in various tissues, without prior knowledge or the need for molecular markers. Further, we demonstrate the potential of our method for inflammatory bowel disease diagnostics. Using unsupervised dimensionality reduction and logistic regression, we accurately differentiate between healthy and tumorous tissue in both mouse and human biopsy samples. The method delivers results within 30 minutes, laying the groundwork for a fast and marker-free diagnostic pipeline to detect pathological changes in solid biopsies.
Competing Interest Statement
S.S., J.L. and J.G. are co-founders of the company Fast Forward Discoveries GmbH, which commercializes the TissueGrinder technology. D.S., M.K. and J.G. are named inventors on a patent application for the combination of TG and RT-DC for solid biopsy diagnosis.
Funding Statement
This study was funded by the DFG (SFB/TRR241 IBDome to R.LP., M.W., R.A. and M.N.; FOR2438 to M.N; DI 1537/20-1, DI 1537/22-1, SFB CRC1181 and SFB TR221 to J.D.) and the IZKF Erlangen (research grant A79 to J.D.).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of the University Hospital of the Friedrich-Alexander University Erlangen-Nuremberg gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The RT-FDC datasets generated and analysed for Fig 2, 3 and Supplementary Fig. 2 and 3 are available on figshare [https://figshare.com/s/2b3a1e1441f59813c24f]. Due to the size restrictions on the figshare repository, the RT-FDC datasets generated from human biopsies samples and mouse tumour samples are available from the corresponding author on reasonable request.
